Millennium reports 5.3% stake in Supernus

Supernus Pharmaceuticals, Inc. received a Schedule 13G filing showing that Millennium Management LLC, Millennium Group Management LLC and Israel A. Englander collectively report beneficial ownership of 3,036,123 shares of Supernus common stock.

Rhea-AI Filing Summary

Supernus Pharmaceuticals, Inc. received a Schedule 13G filing showing that Millennium Management LLC, Millennium Group Management LLC and Israel A. Englander collectively report beneficial ownership of 3,036,123 shares of Supernus common stock. This represents 5.3% of the outstanding common shares as of the event date.

The reporting persons have shared voting and dispositive power over all 3,036,123 shares, with no sole voting or dispositive power. They certify that the shares were not acquired for the purpose of changing or influencing control of Supernus, indicating a passive investment stance.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What ownership stake in Supernus Pharmaceuticals (SUPN) did Millennium report?

Millennium and related parties reported beneficial ownership of 3,036,123 shares of Supernus Pharmaceuticals common stock, representing 5.3% of the outstanding class. This crosses the 5% threshold that requires public disclosure on a Schedule 13G filing.

Who are the reporting persons on this Supernus (SUPN) Schedule 13G?

The reporting persons are Millennium Management LLC, Millennium Group Management LLC, and Israel A. Englander. The filing explains their control relationships, with Millennium Management and related entities exercising voting and investment discretion over the reported Supernus shares.

How much voting power does Millennium have over Supernus (SUPN) shares?

The reporting persons disclose shared voting power over 3,036,123 shares of Supernus common stock and no sole voting power. They also report shared dispositive power over the same number of shares, reflecting coordinated control over how these shares are voted and disposed of.

Is Millennium’s Supernus (SUPN) position intended to influence control of the company?

The filing states the securities were not acquired and are not held to change or influence control of Supernus. It characterizes the position as a passive investment and expressly disclaims any control-related purpose, consistent with a Schedule 13G certification.

When did Millennium’s reportable Supernus (SUPN) ownership position arise?

The Schedule 13G lists January 26, 2026 as the date of the event requiring the filing. That date reflects when Millennium and related reporting persons crossed or were at the 5% beneficial ownership level in Supernus common stock that triggers public disclosure.

Does Israel A. Englander personally own the reported Supernus (SUPN) shares?

The filing explains that the Supernus securities are held by entities subject to voting control and investment discretion of Millennium Management and other managers. It notes this should not be construed by itself as an admission of beneficial ownership by Israel A. Englander personally.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 02/02/2026 - 04:33 PM Learn about SEC filing dates

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

Supernus Pharmaceuticals, Inc.

(Name of Issuer)

Common Stock, par value $0.001 per share

(Title of Class of Securities)

868459108

(CUSIP Number)

01/26/2026

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

SCHEDULE 13G

CUSIP No. 868459108

1

Names of Reporting Persons

Millennium Management LLC

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 3,036,123.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 3,036,123.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

3,036,123.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

5.3 %

12

Type of Reporting Person (See Instructions)

OO

SCHEDULE 13G

CUSIP No. 868459108

1

Names of Reporting Persons

Millennium Group Management LLC

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 3,036,123.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 3,036,123.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

3,036,123.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

5.3 %

12

Type of Reporting Person (See Instructions)

OO

SCHEDULE 13G

CUSIP No. 868459108

1

Names of Reporting Persons

Israel A. Englander

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 3,036,123.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 3,036,123.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

3,036,123.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

5.3 %

12

Type of Reporting Person (See Instructions)

IN

SCHEDULE 13G

Item 1.
(a)	Name of issuer: Supernus Pharmaceuticals, Inc.
(b)	Address of issuer's principal executive offices: 9715 Key West Avenue, Rockville, Maryland 20850
Item 2.
(a)	Name of person filing: Millennium Management LLC Millennium Group Management LLC Israel A. Englander
(b)	Address or principal business office or, if none, residence: Millennium Management LLC 399 Park Avenue New York, New York 10022 Millennium Group Management LLC 399 Park Avenue New York, New York 10022 Israel A. Englander c/o Millennium Management LLC 399 Park Avenue New York, New York 10022
(c)	Citizenship: Millennium Management LLC - Delaware Millennium Group Management LLC - Delaware Israel A. Englander - United States
(d)	Title of class of securities: Common Stock, par value $0.001 per share
(e)	CUSIP No.: 868459108
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: See response to Item 9 on each cover page.
(b)	Percent of class: See response to Item 11 on each cover page.
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: See response to Item 5 on each cover page.
	(ii) Shared power to vote or to direct the vote: See response to Item 6 on each cover page.
	(iii) Sole power to dispose or to direct the disposition of: See response to Item 7 on each cover page.
	(iv) Shared power to dispose or to direct the disposition of: See response to Item 8 on each cover page. The securities disclosed herein as potentially beneficially owned by Millennium Management LLC, Millennium Group Management LLC and Mr. Englander are held by entities subject to voting control and investment discretion by Millennium Management LLC and/or other investment managers that may be controlled by Millennium Group Management LLC (the managing member of Millennium Management LLC) and Mr. Englander (the sole voting trustee of the managing member of Millennium Group Management LLC). The foregoing should not be construed in and of itself as an admission by Millennium Management LLC, Millennium Group Management LLC or Mr. Englander as to beneficial ownership of the securities held by such entities.
Item 5.	Ownership of 5 Percent or Less of a Class.
	Not Applicable
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	If a group has filed this schedule pursuant to §240.13d-1(b)(1)(ii)(K), so indicate under Item 3(k) and attach an exhibit stating the identity and Item 3 classification of each member of the group. If a group has filed this schedule pursuant to §240.13d-1(c) or §240.13d-1(d), attach an exhibit stating the identity of each member of the group. See Exhibit I
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Millennium Management LLC

Signature:	/s/ Gil Raviv
Name/Title:	Gil Raviv, Global General Counsel
Date:	01/30/2026

Millennium Group Management LLC

Signature:	/s/ Gil Raviv
Name/Title:	Gil Raviv, Global General Counsel
Date:	01/30/2026

Israel A. Englander

Signature:	/s/ Israel A. Englander
Name/Title:	Israel A. Englander
Date:	01/30/2026

Exhibit Information

Exhibit I: Joint Filing Agreement, dated as of January 30, 2026, by and among Millennium Management LLC, Millennium Group Management LLC and Israel A. Englander.